The UK and US have forged a key commercial pact that will ensure zero levies on UK drug products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the NHS. This commitment ensures that tariffs on these crucial products will be held at nothing for a period of the next three years.
This agreement comes after previous threats to hike duties on branded pharmaceutical products, with figures floated as high as one hundred percent.
"This arrangement with the UK strengthens the international landscape for innovative medicines and introduces long-overdue balance to American-British medicine commerce," an announcement said.
Trade Impact
Medicines are one of the UK's most significant goods shipped to the US, which is by far the primary market for major companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of last September, the UK sold drugs valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that span.
"This deal secures work, stimulates funding and facilitates the UK to establish itself as a global hub for life sciences," a minister stated.
Detailed NHS Changes
The agreement entails several key changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to increase total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. Last year, rebates topped 20%.
Recent Tensions
This agreement takes place against a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were heightened by arguments that American customers were charged several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the last ten years.
